Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 2
1951 1
1952 1
1953 2
1956 1
1957 2
1958 1
1959 1
1960 2
1961 2
1962 1
1963 4
1964 25
1965 17
1966 8
1967 16
1968 15
1969 20
1970 19
1971 20
1972 31
1973 45
1974 42
1975 39
1976 56
1977 76
1978 75
1979 88
1980 111
1981 105
1982 98
1983 98
1984 110
1985 120
1986 131
1987 103
1988 98
1989 109
1990 104
1991 112
1992 155
1993 129
1994 166
1995 147
1996 148
1997 182
1998 182
1999 214
2000 175
2001 216
2002 192
2003 184
2004 201
2005 226
2006 207
2007 218
2008 235
2009 225
2010 291
2011 255
2012 296
2013 264
2014 305
2015 350
2016 305
2017 318
2018 334
2019 307
2020 349
2021 396
2022 359
2023 355
2024 114

Text availability

Article attribute

Article type

Publication date

Search Results

9,151 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant Hypothalamic Neoplasm"
Page 1
Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL, Mete O, Perry A, Osamura RY. Asa SL, et al. Endocr Pathol. 2022 Mar;33(1):6-26. doi: 10.1007/s12022-022-09703-7. Epub 2022 Mar 15. Endocr Pathol. 2022. PMID: 35291028 Review.
The new classification clearly distinguishes anterior lobe (adenohypophyseal) from posterior lobe (neurohypophyseal) and hypothalamic tumors. Other tumors arising in the sellar region are also discussed. ...Although these historical terms are entrenched in the literature, …
The new classification clearly distinguishes anterior lobe (adenohypophyseal) from posterior lobe (neurohypophyseal) and hypothalamic …
The Diagnosis and Treatment of Craniopharyngioma.
Müller HL. Müller HL. Neuroendocrinology. 2020;110(9-10):753-766. doi: 10.1159/000504512. Epub 2019 Nov 4. Neuroendocrinology. 2020. PMID: 31678973 Free article. Review.
Further research to elucidate pathogenic mechanisms and hopefully prevent hypothalamic involvement of CP is warranted. If the tumor is favorably localized, the therapy of choice is complete resection, with care taken to preserve the optical and hypothalamic function …
Further research to elucidate pathogenic mechanisms and hopefully prevent hypothalamic involvement of CP is warranted. If the tumor i …
National UK guidelines for the management of paediatric craniopharyngioma.
Gan HW, Morillon P, Albanese A, Aquilina K, Chandler C, Chang YC, Drimtzias E, Farndon S, Jacques TS, Korbonits M, Kuczynski A, Limond J, Robinson L, Simmons I, Thomas N, Thomas S, Thorp N, Vargha-Khadem F, Warren D, Zebian B, Mallucci C, Spoudeas HA. Gan HW, et al. Lancet Diabetes Endocrinol. 2023 Sep;11(9):694-706. doi: 10.1016/S2213-8587(23)00162-6. Epub 2023 Aug 4. Lancet Diabetes Endocrinol. 2023. PMID: 37549682 Review.
Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic-pituitary region in childhood. Despite being benign, the close proximity of these tumours to the visual pathways, hypothalamus, and pituitary gland means that both treatment of the tumour …
Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic-pituitary region in childhood. Despite being be …
Childhood-onset Craniopharyngioma.
Otte A, Müller HL. Otte A, et al. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3820-e3836. doi: 10.1210/clinem/dgab397. J Clin Endocrinol Metab. 2021. PMID: 34086900 Review.
The treatment of choice in case of favorable tumor location (without hypothalamic involvement) is complete resection. It is important to ensure that optical and hypothalamic functionality are preserved. ...Severe impairment of quality of life and comorbidities such …
The treatment of choice in case of favorable tumor location (without hypothalamic involvement) is complete resection. It is important …
Craniopharyngioma.
Müller HL. Müller HL. Endocr Rev. 2014 Jun;35(3):513-43. doi: 10.1210/er.2013-1115. Epub 2014 Jan 27. Endocr Rev. 2014. PMID: 24467716 Review.
If the tumor is favorably localized, the therapy of choice is complete resection, with care taken to preserve optical and hypothalamic functions. In patients with unfavorable tumor localization (i.e., hypothalamic involvement), recommended therapy is a limited hypot …
If the tumor is favorably localized, the therapy of choice is complete resection, with care taken to preserve optical and hypothalamic …
Craniopharyngiomas.
Hamblin R, Tsermoulas G, Karavitaki N. Hamblin R, et al. Presse Med. 2021 Dec;50(4):104078. doi: 10.1016/j.lpm.2021.104078. Epub 2021 Oct 22. Presse Med. 2021. PMID: 34688870 Review.
Occurring both in child and adulthood, their clinical manifestations are broad, commonly with symptoms/signs secondary to hypothalamic-pituitary dysfunction, raised intracranial pressure and visual compromise. ...Long term management by an experienced multidisciplinary tea …
Occurring both in child and adulthood, their clinical manifestations are broad, commonly with symptoms/signs secondary to hypothalamic …
Craniopharyngioma.
Müller HL. Müller HL. Handb Clin Neurol. 2014;124:235-53. doi: 10.1016/B978-0-444-59602-4.00016-2. Handb Clin Neurol. 2014. PMID: 25248591 Review.
Therapy of choice in patients with favorable tumor localization is complete resection with specific focus on maintaining functions of the optic nerve and hypothalamic-pituitary axes. In patients whose unfavorable tumor localization makes maintaining hypothalamic fun …
Therapy of choice in patients with favorable tumor localization is complete resection with specific focus on maintaining functions of the op …
Management of Hypothalamic Obesity.
Müller HL. Müller HL. Endocrinol Metab Clin North Am. 2020 Sep;49(3):533-552. doi: 10.1016/j.ecl.2020.05.009. Epub 2020 Jul 15. Endocrinol Metab Clin North Am. 2020. PMID: 32741487 Review.
Energy homeostasis, appetite, and satiety are modulated by a complex neuroendocrine system regulated by the hypothalamus. Dysregulation of this system resulting in hypothalamic obesity (HO) is caused by brain tumors, neurosurgery, and/or cranial irradiation. Craniopharyngi …
Energy homeostasis, appetite, and satiety are modulated by a complex neuroendocrine system regulated by the hypothalamus. Dysregulation of t …
Galactorrhea: Rapid Evidence Review.
Bruehlman RD, Winters S, McKittrick C. Bruehlman RD, et al. Am Fam Physician. 2022 Dec;106(6):695-700. Am Fam Physician. 2022. PMID: 36521467
Galactorrhea is more often the result of hyperprolactinemia caused by medication use or pituitary microadenomas, and less often hypothyroidism, chronic renal failure, cirrhosis, pituitary macroadenomas, hypothalamic lesions, or unidentifiable causes. A pregnancy test shoul …
Galactorrhea is more often the result of hyperprolactinemia caused by medication use or pituitary microadenomas, and less often hypothyroidi …
Childhood craniopharyngioma.
Müller HL. Müller HL. Pituitary. 2013 Mar;16(1):56-67. doi: 10.1007/s11102-012-0401-0. Pituitary. 2013. PMID: 22678820 Review.
Therapy of choice in children with favorable tumor localization is complete resection with the intention to maintain optic nerve and hypothalamic-pituitary functions. In children with unfavorable tumor localization (hypothalamic involvement), a limited resection fol …
Therapy of choice in children with favorable tumor localization is complete resection with the intention to maintain optic nerve and hypo …
9,151 results